Snowball logo
logo
VIRX

Viracta Therapeutics Inc

VIRX • NASDAQ
$0.00978$0.00  (0%)
Estimate
EPS
-1.1
Beta
0.276
Forecast
EPS (FWD)
-0.385
About the company
Ticker
VIRX
ISIN
US92765F1084
Country
United States of America
Sector (GICS)
Healthcare
Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. The company's lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. It's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.

Frequently asked questions

What sector does Viracta Therapeutics Inc (VIRX) operate in?

Viracta Therapeutics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.

What is Viracta Therapeutics Inc (VIRX) current stock price?

As of the latest data, Viracta Therapeutics Inc stock price is $0.01, with a previous close of $0.01.

What is Viracta Therapeutics Inc (VIRX) current market capitalization?

Viracta Therapeutics Inc market cap is approximately 388.70 thousand.

What is Viracta Therapeutics Inc (VIRX) Earnings Per Share (EPS)?

The trailing EPS is -$1.10, and the forward EPS is -$0.39.

Does Viracta Therapeutics Inc (VIRX) pay dividends?

No. Viracta Therapeutics Inc does not pay a dividend.

What is Viracta Therapeutics Inc (VIRX) beta (volatility) score?

Viracta Therapeutics Inc has a beta of 0.276, indicating lower volatility than the overall market.